Skip to main content
OpenTrials
Completed

NCT Number: NCT04160286

The Danish Neuropsychological Study of the Adverse Effects of ECT

The main purpose of this study is to investigate the adverse cognitive side-effects of electroconvulsive therapy (ECT). The second aim is to investigate the mechanisms of effect of ECT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mental Health Services of the Capital Region of Denmark

Copenhagen, 2100, Denmark

About this study

ECT has been the most effective treatment of depression for decades. Despite of this, neither the mechanism of action or side-effects are fully elucidated. The reason why some patients relapse shortly after remission is still not completely understood. Thus, there is a need to find predictors of the favourable clinical effect, relapse and side-effects. ECT is considered by professionals to be a safe procedure. Additionally, many patients do not consent to this treatment because they fear a permanent loss of memory or that they will contract a brain damage after the completed ECT series. Therefore, it is very important to examine whether ECT might have negative effects on the structure or function of the brain, using state of the art Magnetic Resonance Imaging (MRI) techniques.

DANSECT is a prospective, observational follow-up study with the aim of examining why cognitive side-effects of ECT occur and potentially find predictors for whom they may affect by investigating the ECT-associated cognitive disturbances, structural brain changes and clinical outcomes. Second, DANSECT examines the mechanisms of effect of ECT.

DANSECT comprises an ECT-group (30 patients) and a clinical control group (30 patients). The former consists of patients with depression receiving ECT, and the latter consists of matched patients with depression treated pharmacologically. The examinations will take place at three time-points; before, immediately after ECT or just before discharge, and 6 months after. DANSECT is a naturalistic clinical project. This means that the number of ECT sessions given to the patients in the ECT-group is up to the referring physician.

The aim of DANSECT is to investigate the cognitive side-effects of ECT. Specifically, the research project aims to examine:

  • Prevalence, extent and persistence of adverse cognitive effects following ECT.
  • Associations between neuroimaging findings and cognitive changes following ECT.
  • Predictors of adverse cognitive effects of ECT.

Hypotheses:

  • Consistency in autobiographical memories will be reduced over time in both study groups. However, the reduction will be significantly larger for the ECT patients after ECT compared to the control group. The group difference is expected to be present at both short-term and long-term.
  • Autobiographical memory deterioration is expected to correlate with volumetric changes of the hippocampi.
  • Processing speed, anterograde memory and executive functions will be temporarily deteriorated after ECT. The cognitive changes will correlate with volumetric brain changes and changes in structural connectivity.
  • Baseline atrophy, age, years of education and cognitive reserve will predict the cognitive side-effects following ECT.
  • Machine learning will reveal patterns and inference enabling the development of a predictive model of clinical and cognitive outcome after treatment with ECT, by combining neuropsychological tests, structural and functional neuroimaging (MRI) and other neurobiological measures.

In addition, the aim of DANSECT is to investigate the mechanisms of effect of ECT. The secondary aims of the project are thus to examine:

  • Clinical, biochemical and neurobiological predictors of response to ECT
  • Clinical, biochemical and neurobiological predictors of relapse of depression after ECT
  • Biochemical and neurobiological mechanisms of response to ECT

Hypotheses:

  • Smaller baseline hippocampal volume is associated with a larger post-pre reduction of depressive symptoms
  • Thinner cortical thickness predicts better clinical improvement
  • The cortisol trajectory before ECT is associated with clinical outcome
  • Elevated peripheral baseline VEGF is associated with a larger post-pre reduction of depressive symptoms
  • Baseline microRNA levels are associated with clinical outcome
  • A higher baseline structural connectivity predicts better clinical improvement
  • A larger post-ECT increase in hippocampal volume, cortical thickness, BDNF and VEGF predicts a lower risk of relapse within six months after an ECT series

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18-95 years
  • admitted at the MHC Glostrup, MHC Amager or MHC Copenhagen (or other Mental Health Centres in the Capital Region)
  • fulfilling the criteria for depression according to ICD-10 and where ECT is planned.
  • must be able to give informed consent to participate in the study

Exclusion criteria

  • Schizophrenia or any other psychotic disorder except for psychotic depression
  • Dependency syndrome according to ICD-10.
  • Severe somatic or neurological condition (e.g. stroke) confounding results
  • Head trauma resulting in unconsciousness for more than 5 minutes
  • Severe psychotic symptoms or suicide impulses making transportation hazardous
  • Contraindications against MRI
  • Pregnancy
  • Maintenance ECT or ECT received during the last 6 months
  • Any form of compulsory treatment
  • Subjects who do not consent to be informed of incidental findings that could have healthcare implications will not be scanned and can thus not be included

Treatment and study plan

Electroconvulsive therapy

Other

Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.

Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)

Primary outcomes

  1. Columbia Autobiographical Memory Interview - Short Form

    Time frame: at baseline (before ECT series)

    Measures consistency in autobiographical memories over time. Scoring: Minimum: 0. Maximum: 60. A higher score means a better cognitive performance.

  2. Columbia Autobiographical Memory Interview - Short Form

    Time frame: at 5 (+/- 2) days after completion of the ECT series

    Measures consistency in autobiographical memories over time. Scoring: Minimum: 0. Maximum: 60. A higher score means a better cognitive performance.

  3. Columbia Autobiographical Memory Interview - Short Form

    Time frame: at follow-up (6 (+/-2) months after the ECT series

    Measures consistency in autobiographical memories over time. Scoring: Minimum: 0. Maximum: 60. A higher score means a better cognitive performance.

Secondary outcomes

  1. Hamilton Depression Rating Scale

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Hamilton Depression Rating Scale 6-item. Scoring: Minimum: 0. Maximum: 22. A higher score means more symptom severity.

  2. The Screen for Cognitive Impairment for Psychiatry

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Screening tool to measure cognitive performance across several cognitive domains. Scoring: Minimum 0. Maximum: Unlimited. A higher score means a better cognitive performance.

  3. Reys complex figure task

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures visuospatial, constructional, executive and anterograde memory abilities. Scoring: Minimum: 0. Maximum: 36. A higher score means a better cognitive performance.

  4. Trail Making Test A

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures psychomotor speed. Scoring: Minimum:0. Maximum: Unlimited. A higher score means a worse cognitive performance.

  5. Trail Making Test B

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures complex psychomotor speed / executive function. Scoring: Minimum:0. Maximum: Unlimited. A higher score means a worse cognitive performance.

  6. Digit span (WAIS-IV)

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures attention span (forwards) and working memory (backwards). Scoring: Minimum: 0. Maximum: 16.

  7. Five Point Test

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures spatial fluency / problem solving. Scoring: Minimum: 0. Maximum: Unlimited. A higher score means a better cognitive performance.

  8. Color-Word Interference Test (D-KEFS)

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures psychomotor speed, meantal flexibility and set-shifting. Scoring: Minimum: 0. Maximum: Unlimited. A higher score means a worse cognitive performance.

  9. Symbol Digit Modalities Test

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures psychomotor speed. Scoring: Minimum: 0. Maximum: Unlimited. A higher score means a worse cognitive performance.

  10. Vividness of Visual Imagery Questionnaire - Danish version

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Measures subjective experience of the vividness of ones mental visual imagery. Scoring: Minimum: 16. Maximum: 80. A higher score means more vividly experienced mental imagery.

  11. Vocabulary (WAIS-IV)

    Time frame: at one time point: at 5 (+/- 2) days after completion of the ECT series

    Measures vocabulary and serves as an estimate of premorbid intellectual ability. Scoring: Minimum: 0. Maximum: 57. A higher score means a better vocabulary.

  12. Cognitive complaints in bipolar disorder rating assessment

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Self-report of experienced cognitive difficulties. Scoring: Minimum: 0. Maximum: 48. A higher score means more symptom severity.

  13. Squire Subjective Memory Questionnaire

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Self-report of experienced memory difficulties. Scoring: Minimum: -72. Maximum: +72. A higher score means a better cognitive function.

  14. Paired Associates Learning (CANTAB)

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Visuospatial pattern localization. Scoring: Minimum 0. Maximum: Unlimited. A higher score (errors) means a worse cognitive performance.

  15. WHO-5

    Time frame: at 3 time points: at baseline (before ECT series), at 5 (+/- 2) days after completion of the ECT series, at follow-up (6 (+/-2) months after the ECT series)

    Self-report of well-being in the last 14 days. Scoring: Minimum: 0. Maximum: 25. A higher score means a better experience of well-being.

Sponsors and collaborators

Lead sponsor

University of Copenhagen

Other

Collaborators

  • Glostrup University Hospital, Copenhagen

Registry information

Acronym: DANSECT

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Nov 12, 2019
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.